comparemela.com

Latest Breaking News On - Developmental therapeutics - Page 3 : comparemela.com

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 - Affimed (NASDAQ:AFMD)

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control

Seoul
Soult-ukpyolsi
South-korea
Ukraine
Chicago
Illinois
United-states
Germany
Mannheim
Baden-wüberg
Texas
Russia

Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024 - Iberonews

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024 - Iberonews
iberonews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iberonews.com Daily Mail and Mail on Sunday newspapers.

China
Bellmunt
Comunidad-autonoma-de-cataluna
Spain
Chinese
Developmental-therapeutics
Molecularly-targeted-agents
Tumor-biology
Saturday-june
Monday-june
Neck-cancer

Antengene To Present One Oral and Four Abstracts at ASCO 2024

/PRNewswire/ Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated.

China
Chicago
Illinois
United-states
Shanghai
Taiwan
Macau
South-korea
Hong-kong
Singapore
Australia
Beijing

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Zhejiang
China
Hong-kong
United-states
Hangzhou
Suzhou
Jiangsu
Chicago
Illinois
Guangzhou
Guangdong
Jilin

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.